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Abstract
Peripheral arterial disease (PAD) impacts approximately eight million people in the
United States [1]. Disease progression leads to chronic ischemic pain, hindering quality
of life. Pharmaceuticals are a typical treatment for pain associated with PAD; but as few
as 30% of patients have a significant reduction of pain (≥50%) [2].
Neurostimulation is commonly used as a treatment for various diseases and injuries,
including Parkinson’s disease and sports-related back and knee injuries [2]. The objective
of the study was to explore neurostimulation and its effect on pain and paresthesia for a
model of acute peripheral ischemia in young college students.
Pain is highly subjective and as a result can be difficult to measure. As a result, various
pain scales and questionnaires exist and are commonly used for self-reported
measurement of pain. Based on literature and prior pilot work, three instruments for
measuring pain were employed to determine which would provide the best signal to noise
ratio. Of all the instruments tested, the McGill Pain questionnaire best showed differences
in pain in this study, with the best signal to noise ratio, and is recommended for future
research and clinical assessment of ischemic pain.
Neurostimulation treatment did not cause a statistically significant reduction in pain.
However, different trends are seen among different patients with some patients having an
apparent decrease in pain with transcutaneous electrical nerve stimulation (TENS)
treatment while others have an apparent decrease in pain with interferential currents
stimulation (IFC) treatment. This indicates that it would be worthwhile to further explore
neurostimulation and determine what causes the differing responses. Based on the
differing responses, neurostimulation should be pursued as a method of ischemic pain
reduction that could be tailored to the specific patient based on what neurostimulation
best helps them.
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Chapter 1- Introduction
1.1 PAD and Ischemia
Peripheral arterial disease (PAD), also known as peripheral arterial occlusive disease
(PAOD), is the reduction of blood flow resulting from narrowed or occluded arteries,
typically associated with atherosclerosis [1]. PAD often results in ischemia, or
insufficient blood supply, in the limbs and is generally associated with pain [1]. PAD
initially involves pain only during exercise, described as intermittent claudication, but
with progression of the disease, patients develop critical limb ischemia, in which they
experience pain at rest; critical limb ischemia pain associated with progressed PAD is
mainly neuropathic pain [2, 3]. Neuropathic pain is a type of chronic pain that can result
when nerve fibers are affected by tissue damage [2]. The nerve fibers may be injured or
dysfunctional as a result of tissue damage due to lack of blood flow in the case of PAD.
Unlike nociceptive pain, the intensity of the pain may change throughout the day, but it
continues throughout the day regardless of activity level [3].
1.2 Neurostimulation
Pain associated with PAD is currently treated using pharmaceuticals, which proves
insufficient for decreasing pain in as many as 60% of patients [2]. Neurostimulation is a
non-pharmaceutical treatment to treat pain, including neuropathic pain, which is very
successful in many other diseases and injuries [2, 4]. Transcutaneous electrical nerve
stimulation (TENS) is a prevalent type of neurostimulation used to treat many different
conditions [5]. TENS is a biphasic pulsed current, producing a square waveform [5].
TENS changes peripheral nervous system activity causing an analgesic effect and
paresthesia [4]. Paresthesia is a sensation caused by pressure on peripheral nerves, often
1

described as “pins and needles”, much like when one would feel when one’s foot “falls
asleep” [4]. Interferential currents stimulation (IFC), is another common form of
neurostimulation used for various therapeutic applications [6, 7]. IFC uses burstmodulated alternating sinusoidal currents, which may be more effective at penetrating
deeper through the skin than TENS [6, 7].The difference in waveform and penetration
may result in different analgesic effects
One of the main objectives of the study was to determine if either or both
neurostimulation modalities reduce pain.
1.3 Pain Scales
To determine the efficacy of the neuromodulation approach, pain must be assessed. Pain
is highly subjective, so assessing pain is challenging; not everyone interprets the same
pain the same way. Given that pain is so subjective, many different metrics have been
developed to capture it. There are many techniques used in clinical and research settings
to assess pain, including pain scales and questionnaires. Numerical Rating Scale (NRS),
Face Pain Scale (FPS), and the Short Form McGill Pain Questionnaire (MPQ) are
common tools for pain assessment used in healthcare [8, 9]. The NRS is very basic,
allowing subjects to rank pain from 0-10 (or in some cases 1-10), with 0 being no pain
and 10 being the worst pain possible. The FPS uses seven faces to gauge an individual’s
pain; the FPS used in this study was developed for healthcare professionals and parents to
aid in the assessment of children’s pain intensity, Appendix D [10]. The short form MPQ
(henceforward referred to as simply MPQ) was developed by Melzak in 1986 after the
success of the long version of the McGill Pain Questionnaire, to be used when the longer
version was not practical [11]. The MPQ has been used in various studies and clinical
2

assessments of chronic ischemic pain associated with PAD [2, 3]. The Questionnaire
includes 11 sensory descriptive words and 4 affective descriptive words, Appendix E.
The individual is asked to describe their pain by ranking each word as none (0), mild (1),
moderate (2), or severe (3). The rankings for each word are added up to provide the MPQ
pain score.
In initial pilot work, the NRS scale was used on its own. The resulting pain data provided
an unclear picture of pain. To get a better idea of what was actually happening with the
pain, the FPS and MPQ were implemented in further pilot studies. For many, it was
unclear what each number on the NRS pain scale meant. With the FPS, participants were
able to visualize their pain, and with MPQ they were able to actually describe what they
were feeling. The pilot studies including all three pain scales provided a better idea of
what was happening with pain.
In pilot work implementing the MPQ, it was found that after treatments, participants
would on their own describe their feeling of the pain with words commonly used to
describe paresthesia. So, in order to capture this, paresthesia descriptive words were
included in addition to the pain words on the MPQ in all subsequent work, Appendix F.
A secondary objective of the study was to determine the efficacy of the pain scales.
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Chapter 2- Methods
2.1 Design
Several pilot studies were conducted, with 8-12 college students per study, leading up to
the small-scale pre-clinical study. The small-scale pre-clinical study included 45 collegeage students. Participants volunteered for participation. Each participant completed a
consent form and a medical-history questionnaire.
For the small-scale pre-clinical study, participants received compensation, in the form of
a $25 gift card, if they refrained from consuming caffeine for the 24 hours prior to
participation.
The study involved young healthy college students, so to study the effect on ischemia,
ischemia was induced. This was done by occluding the lower arm of the dominant hand
with a manual sphygmomanometer for treatments with occlusion.
There were six treatments: placebo without occlusion (P-), placebo with occlusion (P+),
TENS without occlusion (T-), TENS with occlusion (T+), IFC without occlusion (I-), and
IFC with occlusion (I+). A random blocked design was used, in which each participant
underwent all six treatments in a random order.
2.2 Experimental Setup and Procedure
The participants were instrumented to measure blood flow, blood pressure, heart rate,
respiration rate, hand grip, and skin temperature (All measurements, aside from pain are
presented in the Master’s thesis by Leah Schafer), Figure 1. A manual
sphygmomanometer was used to occlude the treatment arm, and a hand dynamometer
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Figure 1 Experimental Setup: (A) Hand grip dynamometer gripped in the dominant hand,
used to perform static hand grip exercises, during exercise phase (B) Optic Laser Doppler
Flowmetry (LDF) skin probes used to measure blood flow (C) Manual sphygmomanometer
used for occlusion of dominant arm (D) Automated BP monitor affixed to the upper
contralateral arm to measure blood pressure (E) TENS/IFC unit (connected to electrodes
were placed on the upper back_(F) Respiration belt to measure breathing rate (G)
moorVMS-LDF data acquisition unit, used to collect blood flow (H) PowerLab DAQ
connected to a laptop (I) Heat thermistor used to measure skin temperature on treatment
hand (hidden beneath hand dynamometer in picture)

was used for performing exercise. During the later pilot studies and the small-scale preclinical study, the face pain scale and MPQ/Paresthesia questionnaire words were posted
on the wall across from the participant (see Appendices D-F for scale and questionnaire).
After the participant completed the health history and consent forms, Appendices A and
B, they sat in the medical chair and were instrumented to measure blood flow, blood
pressure, respiration, and grip strength. The neurostimulation electrodes were placed on
the participant’s back at the C7 and T4 vertebrae locations, approximately 3 cm to the left
and right of the vertebral column, Figure 2. For the treatments with TENS or IFC, the
frequency was set to 100 Hz and pulse duration to 200 μs. The intensity of the
neurostimulation was increased by increments of one millivolt until the sensory threshold

5

was reached, specifically the threshold in which the participant could feel the
neurostimulation but there was no pain or muscle twitching.

Figure 2 Electrodes Placement on Subject's Back, electrodes
were placed at C7 and T4 vertebrae

NRS and FPS pain (Number pain 0-10 and Face A-G) were assessed every minute
throughout all phases and the McGill Pain/Paresthesia Questionnaire was performed
halfway through both the exercise and occlusion phase. For the questionnaire, each word
was read to the participant and the participant was asked to respond “none”, “mild”,
“moderate”, or “severe” based on the pain they were feeling in their treatment arm.
Each treatment began by collecting one minute of baseline measurements, then
progressed to the Exercise stage, in which the maximum strength was determined through
three maximal contractions lasting 1 second each. The participant then maintained their
grip on the hand dynamometer at 25±5% of their maximum grip for three minutes. After
three minutes the manual sphygmomanometer was inflated to 180 mmHg to occlude
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blood flow and the participant released the hand grip dynamometer. The cuff was inflated
for three minutes, before a one minute recovery stage. For treatments without occlusion,
the manual sphygmomanometer was not inflated.
The participant was allowed to rest roughly 10-15 minutes between each treatment to
ensure that they returned to baseline. The protocol was then repeated for each treatment
in random order for each participant.
2.3 Statistical Methods
For the number and face pain data, a binary logistic regression model was used to
compare differences in pain between TENS, IFC, and placebo.
The responses for the MPQ/Paresthesia Questionnaire data, were converted into
numerical form by assigning “none” with 0, “mild” with 1, “moderate” with 2, and
“severe” with 3. The numerical questionnaire data was analyzed using an ANOVAGeneral Linear Model to compare the different treatments.

7

Chapter 3- Results
3.1 Pilot Studies Results
The initial objective of the pilot studies was to determine if the pain scale(s) being used
were adequate to capture the changes in pain, and which pain scale could best do this.
The follow-up objective was to determine which of the pain metrics was best.
From the initial pilot studies using only the NRS rating scale, most participants had a
change of pain of either 0 or 1. The results showed no difference between the
neurostimulation modalities and their ability to reduce pain compared to placebo.
Later pilot studies using the FPS and the MPQ pain scales still did not show a significant
difference in change in pain for TENS or IFC compared to placebo. The MPQ pain scale,
however, did result in being able to detect larger changes in pain ranging from 1 to 8.
3.2 Small-Scale Pre-Clinical Study Results
The main objective of the small-scale pre-clinical study was to determine whether TENS
or IFC would have an effect on pain, especially during occlusion. A secondary objective was to
determine the efficacy of the pain scales, specifically the MPQ scale, which pilot work indicated
to be the best metric.

8

3.2.2 Numerical Rating Scale Results
During exercise, neurostimulation had a varying effect on change in pain in different
participants, Figure 3. Overall, TENS and IFC were both slightly more likely to have an

Figure 3 Line Plot of Mean Change in NRS Pain during the Exercise Phase, for each participant

increase in NRS pain during exercise as compared to Placebo (Placebo:IFC-odds ratio
0.7889; IFC:Placebo- odds ratio 1.2905). TENS was very slightly more likely than IFC to
cause an increase in pain during exercise (TENS:IFC-odds ratio 1.2905). Though none of
these trends were statistically significant (Figure 4).

9

Figure 5 Main Effects Plots for Change in Pain during the Exercise Phase

During the next phase of the experiment, occlusion, the trends change in NRS pain varied

Figure 4 Line Plot of Mean Change in NRS Pain during the Occlusion Phase for each Participant

widely by participant, as it did in the exercise phase, Figure 5. Placebo treatment is
slightly more likely than the IFC treatment to have an increase in pain during occlusion

10

(odds ratio of 1.1438). TENS is slightly less likely to have an increase in pain during
occlusion than both IFC and Placebo (odds ratios T:I 0.7294 and T:P 0.6377, Figure 6.
Treatments with ischemia are much more likely to have an increase in pain than
treatments without ischemia (odds ratio with occlusion (+): without occlusion (-) is
9.1261), Figure 6. The difference between with and without ischemia was significant.
The differences between neurostimulation were not significant.

Figure 6 Main Effects Plot for Change in NRS Pain during the Occlusion Phase

3.2.3 Face Pain Scale Results
The Face Pain Scale data varies greatly by participant, Figure 7. Placebo is slightly more
likely than both IFC and TENS to have an increase in FPS score during exercise (odds
ratios P:I 1.2286 and T:P 0.8617). TENS is slightly more likely than IFC to have an
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increase in FPS pain during exercise (odds ratio T:I 1.0587). These relationships between
neurostimulation, Figure 8, are not statistically significant.

Figure 7 Line Plot of Mean Change in Face Pain during the Exercise Phase
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Figure 8 Main Effects Plot for Change in Face Pain during the Exercise Phase

Similarly to the exercise phase, the occlusion phase shows great variability between
participant changes in pain with different neurostimulation, Figure 9. Placebo is slightly
less likely than both TENS and IFC to have an increase in FPS Pain during the occlusion

Figure 9 Line Plot of Mean Change in Face Pain during the Occlusion Phase, for each participant

13

phase (odds ratios P:I 0.7275 and T:P 1.3158). TENS is very slightly less likely to have
an increase in FPS during occlusion than IFC (odds ratio T:I 1.9572). These trends in
neurostimulation were not statistically significant, Figure 10. Treatments with ischemia
are considerably more likely to have an increase in pain than treatments without ischemia
(odds ratio 8.5105). The significant difference between with and without ischemia is
illustrated by the steep slope in the ischemia panel of the Main Effects Plot, Figure 10.

Figure 8 Main Effects Plot for Change in Face Pain during the Occlusion Phase

3.2.4 McGill Pain Questionnaire plus Paresthesia Questionnaire
The results of McGill Pain and Paresthesia Questionnaires scores together during the
exercise phase showed that participant change in pain varied significantly (p-value
0.000). Neither ischemia nor neurostimulation affected reported pain during the exercise
phase (p-values of 0.288 and 0.539 respectively). These results are illustrated by the Main
Effects plot, Figure 11, which shows that the points for the different participants vary a
great deal, whereas the points for IFC, TENS, and Placebo for neurostimulation in the
upper right panel, and with and without ischemia in the lower left panel are relatively the
14

same. The interaction between ischemia and neurostimulation was also not statistically
significant (p-value of 0.078), Figure 12.

Figure 10 Main Effects Plot for MPQ plus Paresthesia during the Exercise Phase

Figure 9 Interaction Plot for MPQ plus Paresthesia during the Exercise Phase

Again, during the occlusion phase, the MPQ and Paresthesia data show participant to be
significant with a great deal of variability (p-value of 0.000). Ischemia does have a
significant effect on change in pain during the occlusion phase, with treatments with
ischemia having an increase in pain compared to without (p-value of 0.000).
Neurostimulation does not have a significant effect on the change in MPQ and
15

Paresthesia score during occlusion (p-value of 0.630). These results are illustrated by the
main effects plot, Figure 13. Participant varies in an irregular manner and ischemia has a

Figure 11 Main Effects Plot for MPQ and Paresthesia during the Occlusion Phase

steeply sloped line with (+) ischemia higher than (-) ischemia. Neurostimulation again
has values that are relatively unchanged. The interaction between neurostimulation and
ischemia is again not significant (p-value of 0.126), illustrated by the similarly sloped
lines in the interaction plot in Figure 14.
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Figure 12 Interaction Plot for MPQ plus Paresthesia during the Occlusion Phase

3.2.5 McGill Pain Questionnaire Pain Score
The MPQ score data on its own shows variability by participant during the exercise phase
as well (p-value of 0.000), Figure 15. Neither ischemia nor neurostimulation
significantly affect the change in MPQ pain only during the exercise phase (p-values
0.063 and 0.897 respectively), Figure 16. Tukey confidence intervals illustrate this as
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well in Figures 17 and 18, since all intervals include 0 the factor levels are not
significantly different.

Figure 13 Line Plot of Mean for MPQ Pain Scores during the Exercise Phase

Figure 14 Main Effects Plot for MPQ Pain Scores during the Exercise Phase
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Figure 15 Tukey Confidence Intervals for Difference of Means between with and without
Ischemia for MPQ Pain Scores during the Exercise Phase

Figure 16 Tukey Confidence intervals for the Difference of Means between Neurostimulation
modalities for MPQ Pain Scores during the Exercise Phase
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The interaction between ischemia and neurostimulation is not statistically significant,
Figure 19.The MPQ score data during occlusion ranges by participant as well, Figure
20. Both participant and ischemia have a significant effect on change in MPQ pain score
during occlusion (p-values of 0.000). Neurostimulation does not significantly change the

Figure 18 Interaction Plot for MPQ Pain Score during the Exercise Phase

Figure 17 Line Plot of Mean MPQ Pain Score by subject during the Occlusion Phase, for each participant
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MPQ-assessed pain during occlusion (p-value 0.918), Figure 21. The interaction
between ischemia and neurostimulation is also not significant during occlusion (p-value
0.104), Figure 22.

Figure 20 Main Effects Plot for MPQ Pain Score during the Occlusion Phase

Figure 19 Interaction Plot for MPQ Pain Score during the Occlusion Phase

3.2.6 Paresthesia Questionnaire Score
Like the MPQ pain scores, paresthesia score varied by participant, Figure 23.
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Paresthesia Questionnaire scores during the exercise phase are significantly affected by
participant and neurostimulation (p-values 0.000 and 0.022 respectively), Figures 24 and
25. TENS increases paresthesia more than placebo during exercise, Figure 25.

Figure 22 Line Plot of Mean Paresthesia Score during the Exercise Phase, for each participant

Figure 21 Main Effects Plot for Paresthesia during the Exercise Phase
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Figure 24 Tukey Confidence Interval for Difference of Mean Paresthesia Score between
Neurostimulation modalities during the Exercise Phase

The interaction between neurostimulation and ischemia is not statistically significant (pvalue of 0.075), Figure 26.

Figure 23 Interaction Plot for Paresthesia during the Exercise Phase

Participant also causes variation in Paresthesia during the occlusion phase (p-value
0.000), Figure 27. During occlusion, ischemia significantly affects the change in
paresthesia (p-values of 0.000), Figure 28. Neurostimulation does not significantly affect
Paresthesia during occlusion (p-value 0.238). The interaction between ischemia and
23

neurostimulation is not significant during occlusion as with exercise, (p-value of 0.080),
Figure 29.

Figure 25 Line Plot of Mean Paresthesia Score during the Occlusion Phase, for each participant

Figure 26 Main Effects Plot for Paresthesia during the Occlusion Phase
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Figure 27 Interaction Plot for Paresthesia score during the Occlusion Phase
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Chapter 4- Discussion
The objectives of this study were to determine the best way of assessing pain and to
determine if either TENS or IFC neurostimulation modalities affect acute ischemic pain.
The MPQ appears to be a better way of assessing the pain caused in this study. A larger
difference in pain can be seen, whereas with the NRS and Face pain scales the differences
in pain detected were small, typically between 0 and 1. For future work, the MPQ would
be recommended for the assessment of pain.
The results of the data provided by the pain scales indicate that neither TENS nor IFC
induce analgesia during either the exercise or occlusion. This may result from the study
being done with all young, healthy participants, in which there was not enough pain to be
able to detect significant changes in pain.
TENS did increase paresthesia during the exercise phase. This may be due to the way in
which TENS interacts with the nervous system. Future research could explore this effect.
Although TENS or IFC neurostimulation did not generally induce analgesia, the
variability between participants suggests that TENS may be efficacious in some patients,
while IFC may be better for others. This may be due to differences between participants,
whether due to individual physiology, gender, athleticism, or other unknown factors.
Further work would include additional replicates and an emphasis on examining different
factors to explore what causes the differing trends between participants.
Due to many participants never reporting any pain, likely due to the use of young, healthy
participants, further studies should be conducted with individuals who actually suffer
from PAD or other diseases causing ischemic pain, and on people from varying age
26

groups. In a study with participants who have the disease, there would be a higher
amount of pain and thus differences in pain would be more easily detected. With
differences in pain more easily detected, a trend may become clearer.
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Conclusion
The results indicated that the MPQ makes it easier to view changes in pain for this type
of simulated pain study than NRS or FPS; the large difference in the pain detected by this
study lead to the recommendation that MPQ be used either in place of or in addition to
the other scales in the assessment for self-reporting pain.
This study did not show neurostimulation to be statistically significant, therefore,
evidence was not found to show that neurostimulation significantly reduces ischemic pain
in young college students. However, different trends were shown in different participants,
which indicate trends toward neurostimulation affecting pain, though differently in
different participants. This leads to the desire for future work to explore the differences in
participants that lead to the differences in effects of neurostimulation. In addition,
neurostimulation may be further explored as a treatment for ischemic pain reduction,
which would need to be personalized for the individual.
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Appendix B: Medical History Questionnaire

MEDICAL HISTORY
*= Required

General Information
Participant:
Name: ___________________________________________________________________________
Contact phone number(s): ___________________________________________________________
Age: _________________________________
Height: _______________________________
Weight: _______________________________

□ Right□ Left

Dominant Hand:

Sex:

□ Male □ Female
Women only answer the following:
Yes

No

□
□

□
□

*Are you currently pregnant?
Are you currently breast-feeding?

Men and women answer the following:
Have you consumed caffeine in the last 12 hours?

□ Yes

□ No

Have you exercised to 50% of your maximum heart rate (moderate exercise) in the last:
48 hours?
12 hours?

□ Yes
□ Yes

□ No
□ No

List any prescription medications you are currently taking:
_____________________________________________________________________________________
Do you have any implantable electrical devices (pacemaker, implantable cardioverter defibrillator, etc.)?

□ Yes □ No

If yes, please list:
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_____________________________________________________________________________________
In the past two months, have you experienced any major injury or significant trauma to your arms or upper

□ Yes

back?

□ No

If yes, please describe:

_____________________________________________________________________________________

Past Medical History
Have you ever experienced any of the following:
Yes

No

□
□
□
□
□
□
□
□
□
□
□
□
□
□
□

□ Heart attack
□ High blood pressure (hypertension)
□ Rheumatic Fever
□ Heart murmur (abnormal heart sound)
□ Arrhythmia (irregular heartbeat)
□ Diseases of the arteries (peripheral artery disease, coronary artery disease, etc.)
□ *Epilepsy or seizures
□ Varicose veins (twisted, enlarged veins)
□ Diabetes or abnormal blood sugar
□ Phlebitis (inflammation of the veins)
□ Stroke
□ Anemia (low red blood cell count)
□ *Dermatitis/eczema (inflammation of the skin)
□ *Pain or tingling sensations in your limbs
□ *Syncope (fainting)

Smoking
Have you ever smoked tobacco?

□ Yes

□ No

If yes, how long did you smoke OR how long have you been smoking? _________________________
How frequently did/do you smoke? ___________________________

Drinking
On average, do you drink more than 1 alcoholic beverage per day?

□ Yes

Do you have a past history of heavy drinking?
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□ No

□ Yes

□ No

Appendix C: Protocol
PROTOCOL FOR STUDY
I.

II.

Setup
1.
2.
3.
4.
5.
6.

Turn on the laptop.
Connect the power supply to PowerLab.
Connect the USB cable from PowerLab to the laptop.
Connect the respiration belt to Input 1 on the front panel of PowerLab.
Connect the Hand Dynamometer to Input 2 on the front panel of PowerLab.
Connect the power supply to the Laser Doppler Flow (LDF) system and turn it
on.
7. Connect the skin probes to Channels 1 and 2 on the LDF system.
8. Connect the BNC cables from the LDF system to Inputs 3 and 4 on the front
panel of PowerLab.
9. Turn on the PowerLab system.
10. Open LabChart on the laptop and open the customized settings file.
i. The raw breath signal in millivolts (mV), the respiratory rate in breaths
per minute (BPM), the handgrip force in Newtons (N), CBF 1 in
perfusion units (PU), and CBF 2 in PU should all be displayed in
LabChart at this point.
Application
1. Seat the participant in a chair with both arms supinated and gently resting on the
tray. Ensure that they are comfortable and properly positioned before continuing.
2. Apply the electrodes to the C7 and T4 vertebrae locations, approximately 3 cm to
the left and right of the vertebral column (Figure 1).†
3. Wrap the respiration belt around the participant’s chest, just below the xiphoid
process.
4. Attach the skin probe connected to Channel 1 of the LDF system to the left arm,
2 cm below the crease of the wrist.
5. Attach the skin probe connected to Channel 2 of the LDF system to the right arm,
2 cm below the crease of the wrist.
6. Wrap the cuff connected to the manual sphygmomanometer around the
participant’s left forearm, 2 cm below the crease of the elbow.
7. Wrap the cuff connected to the blood pressure monitor around the participant’s
right arm.
8. Instruct the participant to loosely grip the Hand Dynamometer in their dominant
hand.
9. Instruct the participant to squeeze the Hand Dynamometer as hard as possible for
a second or two, and then relax their grip.*
10. Determine Maximum Voluntary Contraction (MVC) by recording the average of
three handgrip trials and calculate 25% of MVC.
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TENS Electrode Placement at the C7 and T4 Regions*

III.

Treatment
1. Begin treatment according to assigned group code.†
2. Every minute, assess the intensity of the participant’s pain via the NPRS. In
addition, halfway through each interval of the treatment i.e. “baseline”,
“exercise”, “occlusion”, and “recovery”, record the participant’s blood pressure
and heart rate from the monitor.
3. Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and slowly
adjust the intensity to just above sensory threshold (no pain or muscle
contraction) by asking the participant when he/she begins to feel a strong, but
comfortable tingling sensation.
4. Begin 1 min metronome and instruct participant to verbalize his or her pain level
every min.
5. Begin 1.5 min metronome and collect BP & HR data every 1.5 min.
6. Begin recording baseline blood flow for 3 minutes at resting heart rate.
7. Place the hand dynamometer in the participant’s left hand. Instruct the participant
to perform a static handgrip exercise for 3 minutes at 25% MVC.
8. Five seconds before exercise completion, inflate the sphygmomanometer cuff to
180 mmHg. !
9. Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording blood
flow.
10. Deflate the cuff immediately and record for 3 minutes.
11. Stop recording.
12. Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at the
end of each interval.
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13. Detach all equipment from the participant and wait at least 10 minutes before
beginning the next treatment.

* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects."
by Vieira, et. al.
† Group codes: Placebo/PECO- (P-), Placebo/PECO+ (P+), TENS/PECO- (T-), TENS/PECO+ (T+), IFC/PECO- (I-), IFC/PECO+
(I+)
! Only if PECO+ group
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Appendix D: Face Pain Scale [14]
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Appendix E: McGill Pain Questionnaire [11]
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Appendix F: Paresthesia Questionnaire
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